FCCC LOGO Faculty Publications
Flaig TW , Spiess PE , Agarwal N , Bangs R , Boorjian SA , Buyyounouski MK , Downs TM , Efstathiou JA , Friedlander T , Greenberg RE , Guru KA , Hahn N , Herr HW , Hoimes C , Inman BA , Jimbo M , Kader AK , Lele SM , Meeks JJ , Michalski J , Montgomery JS , Pagliaro LC , Pal SK , Patterson A , Petrylak DP , Plimack ER , Pohar KS , Porter MP , Preston MA , Sexton WJ , Siefker-Radtke AO , Tward J , Wile G , Johnson-Chilla A , Dwyer MA , Gurski LA
NCCN Guidelines Insights: Bladder Cancer, Version 5.2018
J Natl Compr Canc Netw. 2018 Sep;16(9) :1041-1053
Back to previous list
The NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with bladder cancer. These NCCN Guidelines Insights discuss important updates to the 2018 version of the guidelines, including implications of the 8th edition of the AJCC Cancer Staging Manual on treatment of muscle-invasive bladder cancer and incorporating newly approved immune checkpoint inhibitor therapies into treatment options for patients with locally advanced or metastatic disease.
1540-1413 Flaig, Thomas W Spiess, Philippe E Agarwal, Neeraj Bangs, Rick Boorjian, Stephen A Buyyounouski, Mark K Downs, Tracy M Efstathiou, Jason A Friedlander, Terence Greenberg, Richard E Guru, Khurshid A Hahn, Noah Herr, Harry W Hoimes, Christopher Inman, Brant A Jimbo, Masahito Kader, A Karim Lele, Subodh M Meeks, Joshua J Michalski, Jeff Montgomery, Jeffrey S Pagliaro, Lance C Pal, Sumanta K Patterson, Anthony Petrylak, Daniel P Plimack, Elizabeth R Pohar, Kamal S Porter, Michael P Preston, Mark A Sexton, Wade J Siefker-Radtke, Arlene O Tward, Jonathan Wile, Geoffrey Johnson-Chilla, Alyse Dwyer, Mary A Gurski, Lisa A Journal Article United States J Natl Compr Canc Netw. 2018 Sep;16(9):1041-1053. doi: 10.6004/jnccn.2018.0072.